2025年12月14日,Terns制药公司股价飙升53%,早期试验结果显示,白血病治疗结果大有希望。 Terns Pharmaceuticals shares surged 53% on Dec. 14, 2025, after early trial results showed promising leukemia treatment results.

2025年12月14日, Terns制药公司股份猛增53%, 临时试验结果显示, 其实验性白血病治疗导致癌症负担大幅降低, Terns Pharmaceuticals shares jumped 53% on December 14, 2025, after interim trial results showed its experimental leukemia treatment produced significant reductions in cancer burden and improved response rates in patients with relapsed or refractory acute myeloid leukemia. 尽管数据是初步的,但治疗对某些病人表现出持久的反应,激发了投资者强烈的兴趣。 The treatment demonstrated durable responses in some patients, prompting strong investor interest despite the data being preliminary. 该公司说,审判仍在进行中,预计很快会取得全部结果。 The company said the trial is ongoing, with full results expected soon.